Fosun Pharma: The holding subsidiary's nebulized solution of Levosalbutamol Hydrochloride has been granted registration approval.

Fosun Pharma announced that recently, its controlling subsidiary, Fosun Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the registration application of its levalbuterol hydrochloride nebulized inhalation solution. The approved indication is for the treatment or prevention of bronchospasm in adults and children over 6 years old. This drug has been independently developed by the group, with a cumulative research and development investment of approximately 5.66 million yuan as of June 2026. In 2025, the sales of this drug in the domestic market are expected to be around 73 million yuan. The approval for market launch will enrich the groups product line, but the sales situation remains uncertain.